Selective GBA2 Inhibitors With Brain Penetration for Neurological Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small-molecule inhibitors of non-lysosomal glucosylceramidase (GBA2) lack selectivity and are not optimized for targeting GBA2, affecting their efficacy in treating diseases associated with dysregulated glucosylceramide metabolism and homeostasis.
Innovation Solution
Development of compounds and prodrugs that selectively inhibit GBA2, specifically designed to target non-lysosomal glucosylceramidase, for treating neurological and liver diseases by modulating glucosylceramide levels and glycosphingolipid metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small-molecule inhibitors like NB-DNJ or AMP-DNM are used to block GBA2 activity, then GBA2 enzymatic activity is inhibited, but the compounds lack selectivity and also inhibit other enzymes including GCase, glucosylceramide synthase, and intestinal alpha-glucosidases
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (cyclic amine core with particular substituent patterns) that create localized binding affinity for GBA2 while avoiding interaction with other enzymes. The molecular structure is optimized to have specific functional groups positioned at precise locations to achieve selective binding to the GBA2 active site.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types, chain lengths, and structural configurations to optimize both selectivity and permeability. The compounds feature modified physicochemical properties compared to prior art inhibitors, including adjusted hydrophobicity and molecular size parameters that enhance brain penetration while maintaining selective GBA2 inhibition.
2Reliability
If existing GBA2 inhibitors are administered, then some GBA2 inhibition is achieved, but the compounds have poor brain permeability and cannot effectively reach neurological disease targets
Solution Approach 1:
The patent applies parameter changes by optimizing molecular properties such as lipophilicity, molecular weight, and hydrogen bonding capacity to enhance blood-brain barrier penetration. The compounds are designed with specific physicochemical parameters that facilitate passive diffusion across the brain endothelium while maintaining adequate GBA2 inhibitory activity.
Solution Approach 2:
The patent uses the cyclic amine molecular scaffold as an intermediary structure that mediates between the requirement for GBA2 binding affinity and the need for brain permeability. This core structure serves as a platform that can accommodate substituents optimized for both enzymatic inhibition and membrane penetration properties.
Data Source
AI summary
The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.